A Phase 2a Single-Dose Study to Evaluate Safety and Efficacy of CS-1103 in Participants With Methamphetamine Use Disorder Not Seeking Treatment Receiving a Single Dose of Methamphetamine

The purpose of the study is to evaluate the safety, efficacy, and pharmacokinetics of four single, increasing doses of CS-1103, given by intravenous (IV) infusion in otherwise healthy, non-treatment seeking participants with methamphetamine use disorder in the presence of a clinically relevant dose of methamphetamine HCl (30 mg IV).

开始日期2025-03-01

申办/合作机构

Clear Scientific, Inc.

[+1]

NCT05971043

/ Not yet recruitingN/AIIT

Skin Disorders in Patients Using Methamphetamine

1. To detect the skin diseases in patients using methamphetamine

开始日期2023-08-03

申办/合作机构

Assiut University

IRCT20120502009620N2

/ RecruitingN/AIIT

Comparing the Effect of Transcranial Direct Current Stimulation (tDCS) With Cognitive-Behavioral therapy (CBT) Interventions on the stress and anxiety and depression and relapse in abstinent methamphetamine-dependent subjects in Farabi Hospital.

开始日期2022-07-23

申办/合作机构

Kermanshah University of Medical Sciences

100 项与盐酸去氧麻黄碱相关的临床结果

登录后查看更多信息

100 项与盐酸去氧麻黄碱相关的转化医学

登录后查看更多信息

100 项与盐酸去氧麻黄碱相关的专利（医药）

登录后查看更多信息

119

项与盐酸去氧麻黄碱相关的文献（医药）

2025-02-01·Analytica Chimica Acta

Insights into the separation, enantioseparation and recognition mechanisms of methamphetamine isotopologues on achiral and polysaccharide-based chiral columns in high-performance liquid chromatography

Article

作者: Kobidze, Giorgi ; Peluso, Paola ; Balloni, Aurora ; Chankvetadze, Bezhan ; Busardò, Francesco Paolo ; Farkas, Tivadar ; Basile, Giuseppe ; Karchkhadze, Marina ; Sprega, Giorgia ; Lo Faro, Alfredo Fabrizio

BACKGROUNDIsotopologues resulting from the labelling of molecules with deuterium have attracted interest due to the isotope effect observed in chemistry and biosciences. Isotope effect may also play out in noncovalent interactions and mechanisms leading to intermolecular recognition. In chromatography, differences in retention time between isotopologues, as well as between isotopomers have been observed resulting in two different elution sequences (isotope effects): the normal isotope effect when heavier isotopologues retain longer than lighter analogues, and the inverse isotope effect featuring the opposite elution order. Although several cases of deuterium isotope effects have been reported so far, the molecular bases of these phenomena remain unclear.RESULTSWe report the separation of isotopologues of methamphetamine (N-methyl-1-phenylpropan-2-amine) (MET), featuring different number and location of deuterium substituents, on an achiral column by high-performance liquid chromatography (HPLC), as well as the simultaneous separation of isotopologues and their enantiomers on some polysaccharide-based chiral columns. The effects of the number and location of deuterium substituents introduced in MET's structure, of the surface chemistry of the adsorbent, and the mobile phase composition and pH on the retention and separation of isotopologues and their enantiomers were examined. In several cases, the effect of temperature was also evaluated, and the thermodynamic quantities associated with isotopologue adsorption, separation, and enantioseparation were also calculated. To elucidate the molecular bases of the experimental observations, quantum mechanics calculations were performed focusing on the vibrational degree of freedom calculated for models of isotopologue-selector complexes. On this basis, zero-point vibrational energies were computed as useful descriptors to differentiate computationally between deuterated isotopologues.SIGNIFICANCEUsing HPLC as experimental technique with the following dual function: 1) separation of MET isotopologues and their enantiomers; 2) exploring noncovalent interactions underlying their separation. The degree of deuteration, location of deuterium substituents, and mobile phase pH play key roles in isotopologue separations. By integrating experimental and computational analyses, noncovalent interactions underlying normal and inverse isotope effects were deconvoluted, highlighting the contribution of hydrogen bond, hydrophobic and dispersive forces in isotopologue and enantiomer separation.

2025-02-01·Toxicology

Methamphetamine inhibits huntingtin-associated protein 1-mediated tyrosine receptor kinase B endocytosis resulting the neuroprotective dysfunction of brain-derived neurotrophic factor

Article

作者: Lv, Mengran ; Shu, Junjie ; Li, Lihua ; Zhang, Xinjie ; Hou, Yuhan ; Wu, Zhenling ; Zhang, Yuan ; Shen, Baoyu ; Dong, Wenjuan ; Jing, Di ; Hou, Zhenping ; Hong, Shijun ; Xu, Jing ; Cao, Yuanyuan ; Yang, Genmeng

Methamphetamine (METH), a synthetic stimulant, has seen an escalating abuse situation globally over the past decade. Although the molecular mechanism underlying METH-induced neurotoxicity has been explored, the dysfunction of brain-derived neurotrophic factor (BDNF) neuroprotection in the context of METH neurotoxicity remains insufficiently understood. Our previous studies have found that METH induced neurotoxicity and BDNF expression in rat primary neurons, necessitating further research into this paradox. Specifically, BDNF-dependent tyrosine receptor kinase B (TrkB) endocytosis was crucial for BDNF to confer neuroprotection in neurons. Therefore, we investigated the effect and molecular mechanism of METH on TrkB endocytosis. This work attempted to explain the potential reasons why BDNF did not exert neuroprotection in the context of METH exposure. In the current study, excessive apoptosis, elevated BDNF and reduced huntingtin-associated protein 1 (HAP1) expression were observed in the hippocampus of METH users. METH also induced cell degeneration, cytotoxicity, and BDNF expression and release in HT-22 cells in both a concentration- (0.25, 0.5, 1, 2, and 4 mM) and time-dependent manner (3, 6, 12, 24, and 48 h). Furthermore, following 24 h of exposure to METH (2 mM), apoptosis, impaired TrkB endocytosis, and reduced HAP1 expression were evident in HT-22 cells and organotypic hippocampal slices from mice. Notably, overexpression of HAP1 attenuated METH-induced cell degeneration, cytotoxicity, apoptosis, and TrkB endocytosis disruption in HT-22 cells. These findings suggest that HAP1 is a key molecule in the disruption of BDNF-mediated neuroprotective signaling by METH, and that targeting HAP1-mediated TrkB endocytosis may represent a promising therapeutic avenue for METH-induced neurotoxicity.

2025-01-01·Biological Psychiatry

Focused Ultrasound Neuromodulation: Exploring a Novel Treatment for Severe Opioid Use Disorder

Article

作者: Rezai, Ali ; Blanke, Olaf ; Tirumalai, Padma ; Mahoney, James J ; Carpenter, Jeffrey ; Marton, Jennifer L ; Meyer, Nathalie ; Adams, Geoffrey ; Hodder, Sally ; Berry, James ; Ranjan, Manish ; D'Haese, Pierre-François ; Arsiwala, Tasneem ; Thompson-Lake, Daisy G Y ; Bhagwat, Aniruddha ; Farmer, Daniel ; Finomore, Victor

BACKGROUNDOpioid use disorder remains a critical healthcare challenge as current therapeutic strategies have limitations resulting in high recurrence and deaths. We evaluated safety and feasibility of focused ultrasound (FUS) neuromodulation to reduce substance cravings and use in severe opioid- and co-occurring substance use disorders.METHODSThis prospective, open-label, single-arm study enrolled 8 participants with severe, primary opioid use disorder with co-occurring substance use. Participants received a 20-minute session of low-intensity FUS (220 kHz) neuromodulation targeting the bilateral nucleus accumbens (NAc) with follow-up for 90-days. Outcome measures included safety, tolerability, feasibility, and effects of FUS neuromodulation by assessment of adverse events, substance craving, substance use (self-report, urine toxicology), mood, neurologic examinations, and anatomic and functional MRI, at 1-, 7-, 30-, 60, and 90- day post-FUS.RESULTSNo serious device-related adverse events or imaging abnormalities were observed. Following FUS, participants demonstrated immediate (p<.002) and sustained (p<.0001; mean 91%) reduction in cue-induced opioid craving with median rating on scale from 0-10: 6.9 (pre-FUS) vs. 0.6 (90-day post-FUS). Craving reductions were similar for other illicit substances (e.g., methamphetamine (p<.002), cocaine (p<.02)). Decreases in opioid and co-occurring substance use were confirmed by urine toxicology. Seven participants remained abstinent at 30-days; 5 remained abstinent throughout 90-days post-FUS. Resting-state functional MRI demonstrated decrease in connectivity from the NAc to reward and cognitive regions post-FUS.CONCLUSIONSNAc FUS neuromodulation is safe and a potential adjunctive treatment for reducing drug cravings and use in individuals with severe opioid- and co-occurring substance use disorders. Larger, sham-controlled, randomized studies are warranted.

项与盐酸去氧麻黄碱相关的新闻（医药）

2024-11-26

·GlobeNewswire-Health Care

Intelligent Bio Solutions Achieves 94.1% Accuracy in Method Comparison Study, Following Positive PK Study Results

Intelligent Fingerprinting Drug Screening System on path to FDA 510(k) submission, expected in the fourth calendar quarter of 2024 INBS will include data from recent PK study alongside results of method comparison study in 510(k) submission NEW YORK, Nov. 26, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced the successful completion of its method comparison study (the “Method Study”) on its Intelligent Fingerprinting Drug Screening System (the “System”). The Method Study confirmed the sensitivity, specificity, accuracy, and usability of the System, validating its potential for use in workplace drug testing and other applications. This milestone follows INBS’ recently announced strong initial results from its Pharmacokinetic (PK) study, both of which are key achievements on the path to the Company’s FDA 510(k) submission. The Method Study was conducted in collaboration with CenExel, a nationwide clinical research site network. It adhered to clinical research standards, including Good Clinical Practice (GCP) guidelines. The Method Study's primary objective was to compare the results of fingerprint sweat opiate screening tests with those obtained using a validated, traceable liquid chromatography-mass spectrometry (LC-MS/MS) method in a laboratory. With a diverse group of 135 healthy donors and nine system operators, the Method Study demonstrated 82.2% sensitivity, 100% specificity, and 94.1% accuracy for the Intelligent Fingerprinting Drug Screening System. Operators found the System easy to use, with no usage errors generated during the course of the study. “The results of our Method Study reaffirm the accuracy and reliability of our fingerprint-based drug screening system,” said Harry Simeonidis, President and CEO at Intelligent Bio Solutions. “By establishing alignment with laboratory-confirmed results through rigorous testing, we have solidified our drug screening system’s credibility for use in safety-critical industries and beyond. This accomplishment is a significant step on our journey toward transforming drug testing with non-invasive technology.” The Method Study evaluated the System’s three core components: the Drug Screening Cartridge, the Drug Screening Reader and the Fingerprint Collection Kit for laboratory analysis. Subjects were randomized and administered codeine doses, then provided fingerprint sweat specimens to assess the System's ability to detect and quantify drug use accurately. The Method Study’s outcomes highlight the System’s reliability, reinforcing its suitability for pre-employment and workplace drug testing applications. If FDA 510(k) clearance were obtained, INBS believes that this would pave the way for the Company to introduce its innovative fingerprint sweat-based drug screening technology to the US market in 2025. As part of the Company's 510(k) submission, which is expected in the fourth calendar quarter of this year, INBS will include data from its recently concluded PK study alongside the results of its Method Study. The Company's clinical study achievements show the accuracy, reliability, and usability of its technology and reinforce the Company's readiness to address the growing demand for drug testing in the US across safety-critical industries such as construction, mining, and transportation, as well as in the law enforcement, drug rehabilitation, and forensic sectors. About Intelligent Bio Solutions Inc. Intelligent Bio Solutions Inc. (NASDAQ: INBS) is a medical technology company delivering innovative, rapid, non-invasive testing solutions. The Company believes that its Intelligent Fingerprinting Drug Screening System will revolutionize portable testing through fingerprint sweat analysis, which has the potential for broader applications in additional fields. Designed as a hygienic and cost-effective system, the test screens for the recent use of drugs commonly found in the workplace, including opiates, cocaine, methamphetamine, and cannabis. With sample collection in seconds and results in under ten minutes, this technology would be a valuable tool for employers in safety-critical industries. The Company’s current customer segments outside the US include construction, manufacturing and engineering, transport and logistics firms, drug treatment organizations, and coroners. For more information, visit: http://www.ibs.inc/ Forward-Looking Statements Some of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. Forward-looking statements in this press release include, without limitation, Intelligent Bio Solutions Inc.’s ability to successfully develop and commercialize its drug and diagnostic tests, realize commercial benefit from its partnerships and collaborations, and secure regulatory approvals, among others. Although Intelligent Bio Solutions Inc. believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. Intelligent Bio Solutions Inc. has attempted to identify forward-looking statements by terminology, including “believes,” “estimates,” “anticipates,” “expects,” “plans,” “projects,” “intends,” “potential,” “may,” “could,” “might,” “will,” “should,” “approximately” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, included in Intelligent Bio Solutions’ public filings filed with the Securities and Exchange Commission. Any forward-looking statements contained in this release speak only as of its date. Intelligent Bio Solutions undertakes no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events. Company Contact:Intelligent Bio Solutions Inc.info@ibs.incLinkedIn | Twitter Investor & Media Contact:Valter Pinto, Managing DirectorKCSA Strategic CommunicationsPH: (212) 896-1254INBS@kcsa.com

临床结果

2023-03-31

·drugs

ADHD Med Prescriptions Spiked Early in Pandemic

FRIDAY, March 31, 2023 -- Prescriptions for attention deficit hyperactivity disorder (ADHD) medications spiked during the COVID-19 pandemic, a new government report shows. The trend may reflect both greater awareness among adults of ADHD symptoms and increased stress driving people to get the care they need. “This report shows there is this growing population of adults who have been diagnosed with ADHD, and there is need for support for this population,” lead study author Melissa Danielson , a statistician with the U.S. Centers for Disease Control and Prevention, told NBC News . Prescriptions for ADHD have been increasing since 2016, according to the CDC researchers, who used insurance data on prescription medication for that year through 2021 in people ages 5 to 64. The study, published March 31 in the CDC publication Morbidity and Mortality Weekly Report, noted that prescriptions filled for stimulant medication increased to 4.1% in 2021 from 3.6% in 2016 among those enrolled in employer-sponsored insurance. The increase was even more pronounced in certain age groups: Among adolescent and adult females ages 15 to 44 and males ages 25 to 44, prescriptions grew 10% from 2020 to 2021. They also rose nearly 20% among females in an even narrower age range, 20 to 24. The medications tracked in the analysis were stimulants sold under the brands Dexedrine and Adderall, methamphetamine under the brand Desoxyn , and methylphenidate , known as Ritalin . A few factors may play into the increases, including greater awareness about symptoms, particularly symptom differences in women; an increase in all mental health diagnoses during the pandemic, and increased access because of changes in how ADHD is diagnosed, NBC News reported. Telehealth may also have played a role. “People tend to seek out diagnoses during times of stress and crisis, and we have anecdotal evidence that there was a significant increase in people seeking diagnoses during the pandemic,” Joshua Langberg , an ADHD specialist and director of the Center for Youth Social Emotional Wellness at Rutgers University in New Jersey, told NBC News. The changes in how ADHD is diagnosed were due to a 2013 update in guidelines in the Diagnostic and Statistical Manual of Mental Disorders. Among the changes included are ADHD symptoms starting later, at age 12 rather than at age 7, to be eligible for a diagnosis, NBC News reported. Adults also need to have fewer symptoms to qualify. Generally, symptoms of ADHD are inattention, hyperactivity-impulsivity, not following through on instructions, not paying close attention to details, losing things and talking excessively. Mental health providers also saw patients via telehealth during the pandemic and prescribed stimulants without seeing patients in person, NBC News reported. “That increased access allowed some people who had flown under the radar, or who said they were doing well enough, to get help,” J. Russell Ramsay , director of the Adult ADHD Treatment and Research Program at the University of Pennsylvania’s Perelman School of Medicine, told NBC News . Ramsay said there has been both over- and underdiagnosis of the disorder. “A comprehensive evaluation for ADHD is time-consuming, can be costly and it involves not just assessing for ADHD, but other things that can lead to concentration issues such as anxiety, depression and lack of sleep,” he explained. Providers sometimes have limited resources to take this into account, and some telehealth companies and pharmacies are being investigated for potentially overprescribing ADHD medication, NBC News reported. “Because ADHD occurs with other mental health disorders half the time, you have to make sure one of those is not causing symptoms of ADHD,” Dr. Lenard Adler , director of the Adult ADHD Program at NYU Langone, told NBC News . “You have to take a careful history.” Sources Morbidity and Mortality Weekly Report , March 31, 2023 NBC News Posted March 2023 Further Support and Information on COVID-19 COVID-19: Prevention & Investigational Treatments COVID-19 Support Group Coronavirus Disease Guide

2023-03-16

·PRNewswire

Myosin Therapeutics Closes Seed Round to Continue Development of Innovative Therapies for Glioblastoma and Stimulant Use Disorder

Myosin Therapeutics Inc., a biotechnology company leveraging its innovative platform technology to identify new molecular entities capable of selectively targeting nanomotor proteins, announced today that it supplemented its National Institutes of Health (NIH) funding with a seed funding round to advance the company's lead programs on glioblastoma and stimulant use disorder. Myosin Therapeutics, Inc. (the "Company") is developing its lead compound, MT-125, to treat glioblastoma, which is a highly aggressive form of brain cancer with a 95% fatality rate and limited treatment options available. In early models, MT-125 has shown that it can simultaneously arrest cancer cell division and migration, and therefore could be a first-in-class therapy. The Company believes that this funding should allow it to reach IND filing for MT-125. Stimulant use disorder, which includes dependence on drugs such as methamphetamine and cocaine, affects millions of people worldwide, is associated with significant morbidity and mortality, and has no FDA-approved treatments. The Company believes that this capital infusion along with existing funding from the National Institute of Health should provide the funding needed to advance Myosin Therapeutics' other lead compound, MT-110, for stimulant use disorders through Phase 1 clinical trials. "We are excited to receive this funding, which will allow us to rapidly advance our first-in-class treatments for glioblastoma and stimulant use disorder, two devastating conditions that lack effective treatments," said Dr. Courtney Miller, co-founder of Myosin Therapeutics. "Our platform for targeting the largely untapped families of nanomotor proteins represents a unique and promising strategy for oncology, in particular." The seed funding round was led by Mint12 Pharma, LLC, with participation from the University of Florida Ventures, DeepWork Capital, and the Florida Opportunity Fund. Mint12 Pharma's Managing Partner, Dave Adams, said, "We are thrilled to partner with Myosin Therapeutics to develop innovative therapies for these two conditions that currently lack effective treatment. Myosin's nanomotor platform has tremendous potential and we look forward to seeing the company's progress in the coming years." About Myosin Therapeutics. Myosin Therapeutics is a Jupiter, FL-based biotechnology company spun out of The Herbert Wertheim UF Scripps Institute (formerly Scripps Research, Florida) focused on develop therapies for central nervous system and oncology indications with a platform for targeting molecular nanomotor proteins. The company's lead programs for glioblastoma and stimulant use disorder target myosin motor proteins, which play a critical role in a wide range of cellular processes. Myosin Therapeutics was founded in 2020 by Drs. Courtney Miller, Patrick Griffin, and Theodore Kamenecka. To learn more about the company, please visit www.myosintherapeutics.com. Mint12 Pharma invests in new patented core pharmaceutical and biotech technologies that have the potential to address fast growing and underserved markets with no current FDA approved therapies by providing financing, placing new executive management to support existing scientific leadership, and governance oversight. Mint12 Pharma provides Seed and Series A financing to companies and is led by an experienced team of Pharma/Biotech operators and investing professionals. SOURCE Myosin Therapeutics Inc.

100 项与盐酸去氧麻黄碱相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	盐酸去氧麻黄碱	N06BA03	-

研发状态

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
注意缺陷障碍伴多动	美国	AJENAT PHARMACEUTICALS LLC	1943-12-31
抑郁症	日本	Sumitomo Pharmaceuticals Co., Ltd.	1941-01-01
发作性睡病	日本	Sumitomo Pharmaceuticals Co., Ltd.	1941-01-01
精神分裂症	日本	Sumitomo Pharmaceuticals Co., Ltd.	1941-01-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


SFN2021	N/A	-	-	Methamphetamine	窪範網淵齋築觸簾構醖(選積網醖鬱願夢壓範淵) = 0.1 mg/kg LEV increased the time spent in the drug-paired chamber, but this data did not reach statistical significance 網夢簾鑰製餘範製衊憲 (顧夢製窪遞窪製醖積構 )	-	2021-11-11
				Levamisole
SFN2018	N/A	甲基苯丙胺依赖	-	Methamphetamine 0.3 mg/kg	鬱範艱襯蓋願範顧遞壓(淵鹹積鬱獵鑰膚顧淵網) = 構襯簾廠廠膚憲糧築鬱醖壓築糧鬱範構廠鬱範 (衊衊蓋廠獵淵顧獵鬱鬱 )	-	2018-11-03
				Methamphetamine 2.0 mg/kg	鬱範艱襯蓋願範顧遞壓(淵鹹積鬱獵鑰膚顧淵網) = 廠衊製製製選製範築獵醖壓築糧鬱範構廠鬱範 (衊衊蓋廠獵淵顧獵鬱鬱 )
SFN2017	N/A	毒性	-	Alcohol	鹹鑰鏇構簾鏇齋鑰鏇餘(製壓壓夢壓廠淵齋襯繭) = 鹽壓糧膚網憲顧鑰簾齋遞廠壓顧憲憲網範憲窪 (願觸製構蓋夢窪鹹鑰廠 ) 更多	-	2017-11-11
				Methamphetamine	顧遞簾憲憲願製網餘餘(獵廠窪糧網壓夢鹽夢鏇) = 製憲餘製廠選選鏇鏇憲鬱襯鏇鬱襯鹽範鏇糧憲 (襯築鏇襯窪簾蓋淵獵膚 ) 更多
SFN2015	N/A	甲基苯丙胺依赖	-	Methamphetamine 1.0 mg/kg	選構餘鬱鏇簾製網衊窪(遞憲襯觸廠鬱鹹鬱淵醖) = 簾衊鹽衊襯窪遞鹽憲醖窪鹽網窪築鏇遞鹽鏇壓 (簾鑰醖築範窪襯窪壓鹹 )	-	2015-10-19
				Methamphetamine 2.0 mg/kg	壓憲醖製願衊積夢網選(繭積製選襯餘糧醖廠齋) = 餘鹹壓鹽齋糧顧糧製鹹廠製鬱壓夢襯憲顧衊衊 (積鏇醖繭築鹹憲鹽餘襯 )
ISC2013	N/A	脑出血 methamphetamine abuse	384	Methamphetamine (Native Hawaiians and other Pacific Islanders)	鑰選襯範衊製範齋鏇願(壓構鹽憲製夢餘築齋遞) = 獵構積選築觸範範艱繭遞蓋觸壓廠壓憲遞窪壓 (蓋網網選積願憲壓鬱築 ) 更多	-	2013-02-01
				Methamphetamine (Non-Hispanic whites)	鑰選襯範衊製範齋鏇願(壓構鹽憲製夢餘築齋遞) = 繭衊選醖鏇糧壓蓋鏇觸遞蓋觸壓廠壓憲遞窪壓 (蓋網網選積願憲壓鬱築 ) 更多
SFN2010	N/A	记忆障碍	-	Saline	(憲醖艱選艱艱觸願鹽餘) = 簾夢鹽鑰製構蓋廠襯網選範願簾選蓋鬱選衊襯 (鏇鹹襯鬱繭構壓鹽選遞 )	-	2010-11-14
				Methamphetamine	(憲醖艱選艱艱觸願鹽餘) = 積製壓鹽願膚窪糧鏇顧選範願簾選蓋鬱選衊襯 (鏇鹹襯鬱繭構壓鹽選遞 )
SFN2008	N/A	甲基苯丙胺依赖	-	Methamphetamine	醖獵鑰鑰鹽壓餘膚廠餘(淵鑰構築膚簾壓鏇廠繭) = The tonic current was significantly increased after chronic meth treatment and withdrawal 鑰網壓膚積膚襯鑰製選 (廠鏇積鹽襯艱鬱範夢夢 )	-	2008-11-17
SFN2005	N/A	甲基苯丙胺依赖	-	Methamphetamine	夢齋醖獵淵鏇積衊艱齋(鏇壓繭鑰製積構鏇觸艱) = 齋範顧艱糧願簾艱淵觸鹹淵鹽淵醖構襯願夢鹹 (齋齋壓夢製觸網繭築鑰 ) 更多	-	2005-11-15
				Placebo	夢齋醖獵淵鏇積衊艱齋(鏇壓繭鑰製積構鏇觸艱) = 製艱顧鑰繭鹹顧夢憲選鹹淵鹽淵醖構襯願夢鹹 (齋齋壓夢製觸網繭築鑰 ) 更多
SFN2003	N/A	-	-	Methamphetamine	製簾膚醖膚構積構遞範(構獵鹽淵繭鹹鏇艱壓淵) = 夢艱餘獵憲鏇鬱築顧憲糧糧衊簾餘鏇範獵膚獵 (鏇製鑰遞糧膚簾鹹製遞 )	-	2003-11-12
				L-NAME (NOs inhibitor)	鏇繭襯鏇範壓鹹齋憲積(廠獵簾觸範鹽齋衊積齋) = 遞憲夢夢糧獵蓋蓋願齋鏇積鏇襯憲繭醖廠獵艱 (網膚齋網壓簾獵膚觸窪 )
SFN2003	N/A	-	-	Methamphetamine	築構製觸觸築蓋構齋簾(遞願襯艱廠觸糧鬱壓鑰) = 觸顧願壓簾夢壓餘繭壓願範夢鏇糧鑰醖選築願 (淵蓋築襯壓夢鑰鹽鬱廠 )	-	2003-11-09
				Amphetamine	築構製觸觸築蓋構齋簾(遞願襯艱廠觸糧鬱壓鑰) = 範鏇襯顧積繭蓋夢廠遞願範夢鏇糧鑰醖選築願 (淵蓋築襯壓夢鑰鹽鬱廠 )